This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore content

  

EventsMaterialsVideosLet's connectLet's ConnectPfizer medical information
Novel Therapieshemophilia_logo.pngNovel TherapiesEventshemophilia_logo.pngAboutAboutWhat is Hemophilia?Hemophilia Burden of DiseaseHeritageDiagnosisDiagnosisSigns and SymptomsInvestigationsTreatmentTreatmentTreatment OptionsNovel TherapiesSupport & ResourcesSupport & ResourcesPatient Support ResourcesHemMobile®Patient Support LeafletsEvents

Investigations

A definitive hemophilia diagnosis is based on a factor assay to demonstrate the deficiency of FVIII or FIX.1

Screening Tests

Screening tests are carried out to determine if coagulation is occurring normally. A number of tests are performed, including platelet function and count, aPTT and PT tests.1

Factor Assays

Diagnosis is confirmed by performing factor assays (FVIII or FIX).1 These tests also assess the level of the clotting factor activity and indicate the severity of the factor deficiency.1

Other Appropriate Tests

People and their families with a history of bleeding disorders should be offered genetic counselling before genetic testing.1 Genetic counselling should also provide information and advice on PND, management of pregnancy and delivery in carriers of hemophilia and PGD.1

Outcome Assessments

A major complication associated with hemophilia is joint damage (arthropathy). It can cause permanent painful damage to the joints, restricting mobility and negatively impacting the quality of life.2,3 ​​​​​

aPTT, activated partial thromboplastin time; FVIII, factor VIII; FIX, factor IX; PGD, pre-implantation genetic diagnosis; PND, prenatal diagnosis; PT, prothrombin time.

References:

Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition [published correction appears in Hemophilia. 2021;27(4):699]. Hemophilia. 2020;26(suppl 6):1-158. Pulles AE, Mastbergen SC, Schutgens RE, Lafeber FPJG, van Vulpen LFD. Pathophysiology of hemophilic arthropathy and potential targets for therapy. Pharmacol Res. 2017;115:192-199.Melchiorre D, Manetti M, Matucci-Cerinic M. Pathophysiology of Hemophilic Arthropathy. J Clin Med. 2017;6(7):63.

   

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

PP-BEN-IND-0024  22/7/22
Diagnosis
About

An overview of hemophilia, including the different types of hemophilia, their causes, consequences and prevalence.
 

What is hemophilia?
Support Your Patients

Pfizer is committed to supporting you and your patients with hemophilia.
Learn more about the patient resources available to support your patients.

Patient support resources
Treatment

Understand the current treatment options and recommendations for patients with hemophilia A and B.
 

Treatment options



PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-BEN-IND-0024

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023